Sildenafil Tablets vs Oral Suspension: What Differs?

Sildenafil Tablets and Oral Suspension: Basic Comparison

The main difference between sildenafil tablets and oral suspension is pharmaceutical form rather than active-drug identity. Both can deliver sildenafil orally, but one uses a discrete solid unit and the other uses a measured volume of liquid containing dispersed drug particles.

Current REVATIO products illustrate the distinction within one brand family: a 20 mg film-coated tablet and a powder that becomes a 10 mg/mL oral suspension after reconstitution.

A separate product, LIQREV, is also a 10 mg/mL sildenafil oral suspension but is supplied ready to use rather than as powder requiring reconstitution.

The broader dosage-form map remains on the sildenafil formulations page.

Solid Tablet vs Liquid Suspension

A sildenafil tablet holds the drug within a solid matrix containing sildenafil citrate and tablet excipients. Its drug content is manufactured into a defined unit before dispensing.

A suspension is physically different because sildenafil-containing particles are dispersed throughout a liquid vehicle rather than being completely dissolved at the molecular level.

That difference creates practical consequences. Tablets do not require redistribution of suspended particles before each use, while a suspension must remain sufficiently uniform so that a measured volume reflects the labeled concentration.

The physical form itself does not determine clinical superiority or faster effect.

Administration Characteristics

Tablets are administered as discrete solid units according to their product labeling. Their physical quantity is represented by the number of tablets and the sildenafil amount in each tablet.

Oral suspension instead requires measurement of a liquid volume corresponding to the product's labeled concentration. Current REVATIO suspension contains 10 mg sildenafil per mL after reconstitution.

Current REVATIO patient instructions specify use of the supplied oral dosing syringe and bottle adaptor. LIQREV labeling likewise recommends a calibrated measuring device for accurate liquid measurement.

These are formulation-handling differences rather than evidence that the active sildenafil behaves as a different drug after systemic absorption.

Preparation Before Use

Finished sildenafil tablets arrive ready as manufactured dosage units and do not require reconstitution.

REVATIO for oral suspension is different: it is supplied as powder and becomes a 10 mg/mL suspension only after labeled reconstitution with a total of 90 mL of water, producing a final volume of 112 mL.

Current patient labeling states that the REVATIO suspension is mixed before it is supplied for use; a bottle that still contains unmixed powder should not be treated as ready-to-use suspension.

LIQREV provides the contrasting liquid model because it is manufactured and supplied as a ready-to-use 10 mg/mL suspension and therefore has no powder-reconstitution stage.

Why Suspension Mixing Matters

Suspended particles can settle or redistribute while a liquid product stands. Mixing before measurement restores a more uniform distribution of the drug throughout the liquid.

Current REVATIO Instructions for Use state that the reconstituted bottle should be shaken for 10 seconds before each use. Current LIQREV labeling similarly instructs shaking well for at least 10 seconds before use.

This is a formulation-specific physical requirement. A manufactured tablet already contains its labeled drug amount within a discrete unit and does not require analogous redistribution immediately before administration.

Mixing instructions should follow the exact product label rather than be generalized to every liquid medicine.

Unit-Based vs Volume-Based Measurement

Tablet and suspension labels express sildenafil quantity in different ways. A tablet gives a fixed milligram amount per unit; a suspension gives a concentration that must be paired with a measured volume.

For example, the REVATIO tablet contains 20 mg sildenafil, while REVATIO suspension contains 10 mg in each milliliter. These statements describe product composition, not a general instruction to convert one formulation into another.

Liquid measurement introduces an additional handling step because the correct volume must be measured with an appropriate device. Household spoons are not equivalent to calibrated pharmaceutical measuring devices.

The strength and concentration concepts are mapped in more detail on the sildenafil strengths page.

Labeled Context Can Differ Between Formulations

Sharing sildenafil as the active drug does not mean that every tablet and every oral suspension belong to the same product label or indication.

REVATIO offers tablet and oral-suspension formulations inside the WHO Group I pulmonary arterial hypertension product family. Generic products can correspond to that PAH formulation context as well.

By contrast, ED-oriented sildenafil tablets commonly use 25 mg, 50 mg and 100 mg strengths and belong to a different labeling framework. Current U.S. sildenafil oral suspensions are not simply liquid versions of every ED tablet product.

The relevant comparison is therefore exact product plus formulation plus indication, not active ingredient alone.

Revatio Suspension and Tablet Context

REVATIO is the most direct same-brand comparison because current labeling includes both a 20 mg tablet and a 10 mg/mL oral suspension.

The tablet is a white to off-white film-coated solid dosage form. The suspension begins as powder containing sildenafil citrate and becomes a 10 mg/mL liquid after reconstitution.

Despite those pharmaceutical differences, current REVATIO labeling reports bioequivalence between the 20 mg tablet and the 10 mg/mL oral suspension when both were administered as a single 20 mg oral sildenafil dose.

That result is formulation-specific evidence and should not be generalized automatically to unrelated sildenafil products. The broader brand framework remains on the sildenafil and Revatio page.

Can Formulation Affect Pharmacokinetics?

Dosage form can theoretically change early drug-release and absorption processes, so pharmacokinetic similarity should be established experimentally rather than inferred from the fact that two products contain the same active ingredient.

For REVATIO, this evidence exists: current labeling states that bioequivalence was established between the 20 mg tablet and the 10 mg/mL oral suspension when administered as a 20 mg single oral sildenafil dose.

A separate FDA clinical pharmacology review for LIQREV also found the ready-to-use 10 mg/mL suspension adequately bridged to the REVATIO 20 mg tablet through bioequivalence for the prespecified Cmax, AUC0-t and AUC0-inf endpoints under fasting conditions.

Bioequivalence addresses systemic exposure under defined study conditions. It does not mean the formulations have identical preparation, storage, measurement or product-handling requirements.

The regulatory PK framework is covered on the sildenafil bioequivalence page.

Liquid Does Not Automatically Mean Faster

A liquid dosage form may remove the tablet-disintegration step, but that observation alone does not establish a faster systemic concentration peak or earlier clinical response.

The REVATIO evidence is especially useful here because its tablet and suspension were shown to be bioequivalent at the studied 20 mg oral dose. The label does not use the liquid form to establish a universally faster onset.

Clinical onset depends on more than dosage-form appearance: absorption, systemic exposure, pharmacodynamic response and clinical context all contribute.

The distinction between concentration timing and observed clinical effect is covered on the sildenafil onset page.

Storage Requirements Can Differ

Storage is one of the clearest practical differences between the tablet and suspension formulations.

Current REVATIO tablets are stored at controlled room temperature of 20°C to 25°C, with permitted excursions to 15°C to 30°C.

REVATIO powder before reconstitution is stored below 30°C in the original package to protect it from moisture. After reconstitution, the suspension can be stored below 30°C or refrigerated at 2°C to 8°C, must not be frozen and is discarded after 60 days.

LIQREV follows yet another liquid-storage framework: 20°C to 25°C, excursions to 15°C to 30°C, no freezing and use within 90 days after first opening.

The complete storage reference remains on the sildenafil storage page.

Expiration and Post-Preparation Handling

Manufactured tablets generally remain governed by the printed package expiration date when stored according to their labeling.

A reconstituted suspension adds a second time point because preparation starts a formulation-specific in-use period. For REVATIO suspension, current labeling defines that period as 60 days from reconstitution.

Ready-to-use LIQREV has a different trigger: its label states that the bottle should be used within 90 days once opened.

These post-preparation or post-opening limits are not interchangeable with the original manufacturer expiration date. The broader stability distinction belongs on the sildenafil expiration page.

Practical Handling Differences

The practical distinction is broader than simply swallowing a solid versus measuring a liquid. Tablets arrive as manufactured units, while suspension handling can involve preparation status, shaking, measuring equipment, container adaptors and product-specific cleaning or storage instructions.

Current REVATIO suspension requires shaking before each use and use of an oral dosing syringe with the bottle adaptor. Its syringe is washed after use according to the Instructions for Use.

LIQREV is already prepared as a suspension but still requires shaking and accurate measurement with a calibrated device.

These features can make a liquid formulation operationally different without establishing that either formulation is universally preferable.

Why Tablets and Suspension Should Not Be Assumed Interchangeable

Bioequivalence and interchangeability are related but different regulatory concepts. The fact that the REVATIO 20 mg tablet and 10 mg/mL suspension were bioequivalent under a defined single-dose study does not mean that any sildenafil tablet can automatically be exchanged for any sildenafil suspension.

ED-oriented 25 mg, 50 mg and 100 mg tablets belong to a different product and indication framework from REVATIO suspension. LIQREV is also a separate approved product even though it contains the same 10 mg/mL sildenafil concentration.

Formulation concentration, product labeling, measuring method, storage and prescribing context therefore remain relevant.

This page compares formulation characteristics and does not provide instructions for switching products or converting an individual regimen.

How to Interpret Sildenafil Tablets vs Oral Suspension

The most useful comparison separates pharmaceutical differences from pharmacokinetic evidence. Tablets and suspensions differ clearly in physical form, measurement, preparation and storage.

At the same time, formulation difference does not necessarily mean different systemic exposure. REVATIO provides direct evidence that its 20 mg tablet and 10 mg/mL suspension can be bioequivalent at the studied 20 mg dose, and LIQREV has separate FDA bridging evidence to the REVATIO tablet.

The correct conclusion is therefore neither 'the formulations are the same' nor 'the liquid must work differently.' They contain the same active drug but remain distinct pharmaceutical products whose PK relationship must be established with product-specific evidence.

For the complete dosage-form overview, the sildenafil formulations page places tablets and suspension alongside oral film and injection.